The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test the company’s GLP-1 analogue semaglutide as a treatment for early Alzheimer’s disease.

Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.

Novo Nordisk ended development of the anti-IL-21 antibody NN9828 in combination with Victoza after analyzing Phase II clinical trial data in patients with Type 1 diabetes.

Many experts are convinced that Covid-19 can trigger the onset of diabetes – even in some adults and children who do not have the traditional risk factors.

The European medicines watchdog recommended approving AstraZeneca’s treatments for a form of heart failure and a lung disorder, the British drugmaker said.

The U.S. Food and Drug Administration approved two additional doses of Eli Lilly and Company’s Trulicity (dulaglutide).

AstraZeneca’s Farxiga improved survival chances for patients suffering from kidney disease, underscoring the medicine’s role outside the drug’s established field of diabetes.

The U.S. Food and Drug Administration removed a boxed warning about increased risk of leg and foot amputations with Johnson & Johnson’s diabetes drug Invokana.